Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-group study of subcutaneous liquid omalizumab prefilled syringe in moderate-to-severe persistent allergic asthma
2006-005917-36Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of omalizumab in allergic asthma and asthma, sponsored by Novartis. Primary endpoints: Adverse events and serious adverse events and Immunogenicity. Started Jun 2007; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on 2006-005917-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005917-36.